News
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are engaged in a battle of sorts. The two won FDA approval for new non-small cell lung cancer therapies in 2015 that work similarly, and
12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline
Pfizer (NYSE: PFE) announced its second-quarter results before the market opened on Tuesday. And investors yawned -- at least for the most part.Many of the headlines about the big drugmaker's
2 Dividend-Growth Stocks That Are Minting Money
If you're looking for a good dividend stock for the long term, it's important to look beyond current dividend yields to the company's prospects for growth and the strength of its free cash flow. A
3 Things You Can Expect With Pfizer's Q2 Results
There was good news and bad news for Pfizer (NYSE: PFE) the last time it reported quarterly results. In May, the big drugmaker announced earnings for the first quarter that beat analysts' estimates
What's Next for AstraZeneca and Its Dividend?
Just over three summers ago, AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot convinced shareholders to reject a generous buyout offer from Pfizer with promises that drugs in its pipeline would deliver
McCain Pulls the Plug on Obamacare "Skinny Repeal" Without Replacement
Republicans have been fighting to repeal and replace the Affordable Care Act since it was passed by Democrats in 2010. After winning Congress and the White House last November, many republicans
Celgene Corporation Continues to Get It Done
Celgene (NASDAQ: CELG) continues to grow revenue with its top-three drugs all experiencing sales growth of at least 20% year over year in the second quarter. The solid quarter allowed management to
Here's Why NuVasive Is Tanking Today
After NuVasive (NASDAQ: NUVA), a medical device maker focused on minimally invasive spine surgery, reported mixed second-quarter earnings results and announced a shake-up in its executive team, its
3 Value Stocks Senior Citizens Should Consider Buying Today
News flash, seniors: the average American's life expectancy has increased by roughly a decade since you were born, meaning now more than ever you'll need to ensure you won't outlive your money. This
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a
Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today
Shares of Integra LifeSciences (NASDAQ: IART), a medical device company that focuses on surgical products, fell as much as 11% in early morning trading on Wednesday after the release of second-quarter
These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now
Despite overcoming a whopping $23 billion in branded patent expirations over the course of 2011 to 2016 and returning to growth on an operational basis, Wall Street thinks Pfizer (NYSE: PFE) still has
Corning Looks to Sustain Its Momentum
Corning Incorporated (NYSE: GLW) is set to announce second-quarter 2017 results this Wednesday, July 26, 2017. With shares trading at a 10-year high after climbing more than 30% year to date as of
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE: PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, Pfizer makes some of
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls
Here's How to Find the Best Dividend Stocks
Finding great income stocks would be easy if the only metric that mattered was yield. If that was true, then an investor would simply screen for the highest-yielding stocks they could find and buy
Rule Breaker Mailbag: Is Corporate Leadership Really as Important as the Fool Says?
In this segment from Rule Breaker Investing, Motley Fool co-founder David Gardner attempts to answer a Foolish investor who is skeptical that the leadership ability and style of CEOs and executive
5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report
It's officially earnings season, which can only mean one thing: Johnson & Johnson (NYSE: JNJ) is kicking things off for big pharmaceutical companies.On Tuesday morning, July 18, Johnson & Johnson